Sartorius reported strong Q2 19 results – beating our estimates as well as the consensus. Sales were up 15.1%, on a cc basis, driven by Bioprocess Solutions (+20.5%), which more than offset the weakness in Lab Products and Services (+0.6%). EBITDA came in at €123.5m (margin +130bp to 26.9%). Management upgraded its FY 19 top-line growth guidance to 10-14% (vs 7-11% earlier) while re-iterating its EBITDA margin expectations (27%). Following the strong Q2 performance, we will be upgr
22 Jul 2019
BPS drives a solid Q2; guidance upgraded
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
BPS drives a solid Q2; guidance upgraded
Sartorius AG (0NIQ:LON) | 13,825 0 0.0% | Mkt Cap: 10,352m
- Published:
22 Jul 2019 -
Author:
Virendra Chauhan -
Pages:
3
Sartorius reported strong Q2 19 results – beating our estimates as well as the consensus. Sales were up 15.1%, on a cc basis, driven by Bioprocess Solutions (+20.5%), which more than offset the weakness in Lab Products and Services (+0.6%). EBITDA came in at €123.5m (margin +130bp to 26.9%). Management upgraded its FY 19 top-line growth guidance to 10-14% (vs 7-11% earlier) while re-iterating its EBITDA margin expectations (27%). Following the strong Q2 performance, we will be upgr